Dosing and uses of Nylidrin
Adult dosage forms and strengths
tablet
- 6mg
Peripheral Vascular Disorders
12-48 mg/day divided TID/QID PO
Organic Mental Disorders
12-24 mg/day divided TID/QID PO
Pediatric dosage forms and strengths
N/A
Nylidrin adverse (side) effects
Frequency not defined
Dizziness
Nausea/Vomiting
Palpitations
Postural hypotension
Trembling
Warnings
Contraindications
Recent MI, progressive angina
Paroxysmal tachycardia
Thyrotoxicosis
Cautions
Cardiac disease (eg, tachyarrhythmias, uncompensated CHF)
Pregnancy and lactation
Pregnancy category: weigh risk/benefit
Lactation: no info, weigh risk/benefit
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Nylidrin
Metabolism: N/A
Excretion: N/A
Mechanism of action
Peripheral vascular disorders: beta receptor stimulator; dilates skeletal muscle arterioles & increases cardiac output
Mechanism of psychopharmacologic actions not known
